[go: up one dir, main page]

NO20050400L - Nytt kombinasjonspreparat - Google Patents

Nytt kombinasjonspreparat

Info

Publication number
NO20050400L
NO20050400L NO20050400A NO20050400A NO20050400L NO 20050400 L NO20050400 L NO 20050400L NO 20050400 A NO20050400 A NO 20050400A NO 20050400 A NO20050400 A NO 20050400A NO 20050400 L NO20050400 L NO 20050400L
Authority
NO
Norway
Prior art keywords
new combination
combination preparation
pde5
cgmp
angiotensin
Prior art date
Application number
NO20050400A
Other languages
English (en)
Inventor
David Nathan Abraham Fox
Bernadette Hughes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20050400L publication Critical patent/NO20050400L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

2005-03-29 Sammendrag O. nr. E38639 Det beskrives kombinasjonspreparater omfattende a) en inhibitor av cyklisk guanosin monofosfat (cGMP) spesifikt fosfodiesterase type 5 (PDE5) og b) en angiotensin II reseptorantagonist som finner anvendelse ved behandling av hypertensjon.
NO20050400A 2002-06-26 2005-01-25 Nytt kombinasjonspreparat NO20050400L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0214784.1A GB0214784D0 (en) 2002-06-26 2002-06-26 Novel combination
PCT/IB2003/002657 WO2004002461A2 (en) 2002-06-26 2003-06-16 Combination of pde5 inhibitors with angiotensin ii receptor antagonists

Publications (1)

Publication Number Publication Date
NO20050400L true NO20050400L (no) 2005-03-29

Family

ID=9939342

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050400A NO20050400L (no) 2002-06-26 2005-01-25 Nytt kombinasjonspreparat

Country Status (20)

Country Link
EP (1) EP1524996A2 (no)
JP (1) JP2005531627A (no)
KR (1) KR20050013156A (no)
CN (1) CN1662257A (no)
AR (1) AR040337A1 (no)
AU (1) AU2003242895A1 (no)
BR (1) BR0312030A (no)
CA (1) CA2491002A1 (no)
GB (1) GB0214784D0 (no)
GT (1) GT200300124A (no)
MX (1) MXPA04012569A (no)
NO (1) NO20050400L (no)
PA (1) PA8575501A1 (no)
PE (1) PE20040868A1 (no)
PL (1) PL375079A1 (no)
RU (1) RU2004136276A (no)
TW (1) TW200404546A (no)
UY (1) UY27863A1 (no)
WO (1) WO2004002461A2 (no)
ZA (1) ZA200409532B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
KR100714349B1 (ko) * 2002-07-26 2007-05-04 올림푸스 가부시키가이샤 화상 처리 시스템
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
BRPI0502411A (pt) * 2005-03-31 2006-11-28 Univ Minas Gerais processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados
MX2007015365A (es) 2005-06-10 2008-02-12 Dong A Pharm Co Ltd Agente para la prevencion y tratamiento de enfermedades hepaticas que contienen el derivado de pirazolopirimidina.
WO2007010337A2 (de) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von adipositas, sowie abgabesysteme für dieselben
WO2007047978A2 (en) * 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2377531A2 (en) * 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
RU2345763C1 (ru) * 2007-04-26 2009-02-10 ФГУ "Московский научно-исследовательский институт психиатрии Федерального агентства по здравоохранению и социальному развитию" Способ купирования и предупреждения побочных сердечно-сосудистых явлений при применении ингибиторов фосфодиэстеразы 5-го типа для лечения расстройств эрекции у мужчин

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
IL135462A0 (en) * 1997-11-12 2001-05-20 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
EA200200240A1 (ru) * 1999-10-11 2002-10-31 Пфайзер Инк. 5-(2-ЗАМЕЩЕННЫЕ-5-ГЕТЕРОЦИКЛИЛСУЛЬФОНИЛПИРИД-3-ИЛ)-ДИГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-7-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
KR20030023747A (ko) * 2000-08-11 2003-03-19 화이자 인코포레이티드 인슐린 저항성 증후군의 치료

Also Published As

Publication number Publication date
ZA200409532B (en) 2006-06-28
TW200404546A (en) 2004-04-01
PA8575501A1 (es) 2003-12-30
EP1524996A2 (en) 2005-04-27
UY27863A1 (es) 2003-12-31
CA2491002A1 (en) 2004-01-08
PL375079A1 (en) 2005-11-14
GT200300124A (es) 2004-03-17
MXPA04012569A (es) 2005-04-19
JP2005531627A (ja) 2005-10-20
CN1662257A (zh) 2005-08-31
AR040337A1 (es) 2005-03-30
RU2004136276A (ru) 2005-09-10
PE20040868A1 (es) 2004-11-25
WO2004002461A3 (en) 2004-05-13
WO2004002461A2 (en) 2004-01-08
KR20050013156A (ko) 2005-02-02
BR0312030A (pt) 2005-03-22
GB0214784D0 (en) 2002-08-07
AU2003242895A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
CY1105390T1 (el) Θepαπευτικη αγωγη της πνευμονικης υπερτασης
WO2002102314A3 (en) Purine inhibitors of phosphodiesterase (pde) 7
NO20050400L (no) Nytt kombinasjonspreparat
DK1123296T3 (da) Pyrazolopyrimidinon cGMP PDE5-inhibitorer til behandling af seksuel forstyrrelse
DK1443925T3 (da) Naphthyridinderivater, deres fremstilling og deres anvendelse som inhibitorer af phosphodiesteraseisoenzym 4 (PDE4)
AR022665A1 (es) Compuestos farmaceuticamente activos
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
NO20024741D0 (no) 8-quinolinxantin og 8-isoquinolinxantinderivater som PDE5- inhibitorer
AP1718A (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
WO2003017936A3 (en) Use of dppiv inhibitors as diuretic and anti-hypertensive agents
EP1397142A4 (en) PYRIMIDINE PHOSPHODIESTERASE (PDE) INHIBITORS 7
DE60214198D1 (de) Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
NO20061072L (no) Doseringsformer som tilveiebringer kontrollert frigivning av kolesterylesteroverfonngsprotetntnhibttorer og umiddelbar frigivning av HMG-COA-reduktase-Inhibitor
DE60130555D1 (de) 1-(heteroaryl-phenyl)-kondensierte pyrazol-derivate als factor xa inhibitoren
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
GB0106661D0 (en) Pharmaceutically active compounds
NO20045517L (no) Ny kombinasjon
IL132853A0 (en) Combination therapy for modulating the human sexual response
DE60121587D1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
EP1496897A4 (en) Tyrosine kinase inhibitor
NO20001548L (no) Endotelinantagonist og en renin-angiotensinsystem inhibitor som et kombinert preparat
CA2472008A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
UY26893A1 (es) Combinación farmacéutica de antagonistas de la angiotensina ii e inhibidores de la enzima de conversión de la angiotensina i

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application